Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sophie M. Ernst"'
Autor:
Sophie M. Ernst, Maaike M. Hofman, Tessa E. van der Horst, Marthe S. Paats, Frank W.J. Heijboer, Joachim G.J.V. Aerts, Daphne W. Dumoulin, Robin Cornelissen, Jan H. von der Thüsen, Peter de Bruijn, Esther Oomen-de Hoop, Ron H.J. Mathijssen, Stijn L.W. Koolen, Anne-Marie C. Dingemans
Publikováno v:
EBioMedicine, Vol 102, Iss , Pp 105074- (2024)
Summary: Background: Sotorasib given after immunotherapy could put patients at increased risk of hepatotoxicity. Therefore, there is a need to gain insight into the potential correlation between anti-PD-(L)1 treatment, anti-PD-(L)1 concentrations, so
Externí odkaz:
https://doaj.org/article/a26effef666d4b159c43d8ae59e8c674
Autor:
Sophie M. Ernst, Joanne M. Mankor, Job van Riet, Jan H. von der Thüsen, Hendrikus J. Dubbink, Joachim G.J.V. Aerts, Adrianus J. de Langen, Egbert F. Smit, Anne-Marie C. Dingemans, Kim Monkhorst
Publikováno v:
Journal of Thoracic Oncology, 18(4), 487-498. International Association for the Study of Lung Cancer
Introduction: Patient-reported smoking history is frequently used as a stratification factor in NSCLC-directed clinical research. Nevertheless, this classification does not fully reflect the mutational processes in a tumor. Next-generation sequencing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00cf9743a1479a3c4eba3c64ec721d08
http://www.scopus.com/inward/record.url?scp=85146015148&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85146015148&partnerID=8YFLogxK
Autor:
Liesbeth M. Hondelink, Sophie M. Ernst, Peggy Atmodimedjo, Danielle Cohen, Janina L. Wolf, Anne-Marie C. Dingemans, Hendrikus J. Dubbink, Jan H. von der Thüsen
Publikováno v:
European Journal of Cancer, 181, 53-61. Elsevier Ltd.
Objectives: The landmark ADAURA study recently demonstrated a significant disease-free survival benefit of adjuvant osimertinib in patients with resected EGFR-mutated lung adenocarcinoma. However, data on prevalence rates and stage distribution of EG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f012a67ee0773d8562e16dba3dae2445
https://doi.org/10.1016/j.ejca.2022.12.010
https://doi.org/10.1016/j.ejca.2022.12.010
Autor:
Christi M.J. Steendam, Sophie M. Ernst, Sushil K. Badrising, Marthe S. Paats, Joachim G.J.V. Aerts, Adrianus J. de Langen, Anne-Marie C. Dingemans
Publikováno v:
Lung Cancer, 181:107248. Elsevier Ireland Ltd
Objectives: In patients with Epidermal Growth Factor Receptor (EGFR)-mutated non-small cell lung (NSCLC) chemotherapy remains standard of care after progression on EGFR-tyrosine kinase inhibitors (TKIs). With the development of anti-angiogenic agents
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb57b730c4db71ca2a8886c943affe95
https://doi.org/10.1016/j.lungcan.2023.107248
https://doi.org/10.1016/j.lungcan.2023.107248
Autor:
Sophie M. Ernst, Ronald van Marion, Peggy N. Atmodimedjo, Evert de Jonge, Ron H. Mathijssen, Marthe S. Paats, Peter de Bruijn, Ron H.N. van Schaik, Hendrikus J. Dubbink, Anne-Marie C. Dingemans
Publikováno v:
Cancer Research. 83:2137-2137
Introduction: The CodeBreaK 200 trial showed that in patients (pts) with advanced KRAS G12C mutated (KRAS+) NSCLC sotorasib, a KRAS G12C-specific inhibitor, is superior to docetaxel for progression free survival (PFS) (HR 0.66) with a one-year PFS of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be3c710a14758704417979726eb63bba
https://doi.org/10.1158/1538-7445.am2023-2137
https://doi.org/10.1158/1538-7445.am2023-2137